Unbound MEDLINE

Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch. Nephron. Clinical practice [Nephron Clin Pract] Journal article

 
TitleEfficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch.
Author(s)Huh KH, Kim SI, Joo DJ, Ju MK, Chang HK, Kim HJ, Kim YS, Kim MS 
InstitutionDepartment of Surgery, Yonsei University College of Medicine, Seoul, Korea.
SourceNephron Clin Pract 2009; 111(1):c49-54.
MeSHAdult
Antilymphocyte Serum
B-Lymphocytes
Female
Graft Rejection
Histocompatibility Testing
Humans
Immunoglobulins, Intravenous
Immunosuppression
Immunosuppressive Agents
Isoantibodies
Kidney Transplantation
Living Donors
Male
Middle Aged
Muromonab-CD3
Mycophenolic Acid
Plasmapheresis
Prednisone
Premedication
Preoperative Care
Reoperation
T-Lymphocytes
Tacrolimus
Transplantation, Homologous
Treatment Outcome
AbstractBACKGROUND: Patients with a positive lymphocyte crossmatch (LCX) do not undergo kidney transplantation. In such patients, a negative conversion protocol consisting of intravenous immunoglobulin (IVIG), plasmapheresis, and potent immunosuppressant is one of the options for transplantation.
METHODS: 14 patients who showed a positive LCX with living donors underwent a trial of negative conversion between January 2002 and July 2007. Plasmapheresis was performed every other day, up to 6 times maximum. IVIG was infused after plasmapheresis, with a total dose of 500 mg/kg divided over 6 days. Kidney transplantation was performed immediately after negative conversion. Anti-thymocyte globulin (ATG) or OKT3 induction therapy was used with the combination of tacrolimus, mycophenolate mofetil, and prednisone in the perioperative period.
RESULTS: Negative conversion of LCX was achieved in 13 of 14 patients (92.9%). Transplantations were performed successfully in these 13 patients without hyperacute rejection. Four recipients developed acute rejection, which was well controlled by steroid pulse therapy. During the follow-up periods of 45.4 +/- 22.0 months, all recipients except 1 showed excellent graft function.
CONCLUSION: Selected patients with a positive LCX can undergo successful transplantation using plasmapheresis, IVIG, and potent immunosuppressants. Recipients with negative conversion of LCX showed acceptable posttransplant results.
Languageeng
Pub Type(s)Clinical Trial
Journal Article
PubMed ID19052470
  
Advertise on this site.